SCHEMBL10153604

SCHEMBL10153604

CCCNC(=O)C1C(=O)N(O)C(=O)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.47
KMT2A Q03164 3/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 2/20 0.43
KCNH2 Q12809 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
ASAH1 Q13510 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10153314 0.92 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL10153707 0.91 KMT2A (0.55) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL9959242 0.90 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL10153662 0.90 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL9959705 0.90 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL9952553 0.90 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL9952669 0.90 KMT2A (0.54) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL9958620 0.85 DRD2 (0.44) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL19380274 0.82 HDAC4 (0.44) KCNA5KMT2AMAPTMEN1KCNH2
SCHEMBL10153701 0.82 POLB (0.57) KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070165-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION SAINT LOUIS UNIVERSITY (US) 2019-03-07 US disclosed
WO-2017161133-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION SAINT LOUIS UNIVERSITY (US) 2017-09-21 WO disclosed
WO-2012085003-A1 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070165-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION HCCS, HAVCR2, HDGF KCNA5 4831/4885KMT2A 2169/4885MAPT 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.